Supplemental Table 1. Details on cancer types, treatments received, eligibility criteria and prognostic factors in 22 SWOG trial arms pooled in analysis

Cancer Type Common Treatment (# of trials)	Trial number (# of study arms included)	Disease Description	N**	Prognostic Factors Included in Regression	Dose/M^2 BSA?	% Alive at 5 years	Total Sample Size
AML Ara-C/DNR (n=5)	S8600 (2)	No prior tx, ≤65 years	761	PS (0-1 v. ≥2), White Blood Count (≤20 v. >20)	Yes	17%	1,259
	S8706 (1)	No prior tx, <=55 years	47				
	S9031 (2)	No prior tx, >55 years	201				
	S9333 (1)	No prior tx, >55 years	153				
	S9500 (1)	No prior tx, <=55 years	97				
Bladder BCG (n=2)	S8507 (2)	Transitional cell, superficial	530	Carcinoma in situ (no v. yes)	No	76%	705
	S8795 (1)	Transitional cell, superficial	175				
Breast * CAF x 6 (n=2)	S8814 (2)	T1-3, N1-2, M0	1118	Nodal status (<4 v. ≥4), tumor size (≤5 v. >5), receptor status (neg v. pos)	Yes	86%	1,594
	S8897 (2)	T1-3, N0, M0, node negative	476				
Breast * CMF x 6 (n=1)	S8897 (2)	T1-3, N0, M0, node negative	484	Tumor size (≤5 v. >5), receptor status (neg v. pos)	Yes	88%	484
Breast * AC+Paclitaxel	S0221 (6)	Stages I-III (no T4)	3145	Nodal status (<4 v. ≥4), tumor size (≤5 v. >5), receptor status (neg v. pos)	Yes	88%	3145
Colorectal 5-FU (n=1)	S9420 (2)	Advanced	673	Disease type (evaluable v. measurable), PS (0-1 v. 2), prior adjuvant chemotherapy (no v. yes), prior surgery (no v. yes)	Yes	2%	673
NHL CHOP (n=2)	S8516 (1)	Aggressive, Advanced	206	International Prognostic Index (low v. low-intermediate v. high-intermediate v. high)	Yes	60%	403
	S8736 (1)	Aggressive, Early	197				
NSCLC Carboplatin+ Paclitaxel (n=2)	S9509 (1)	Advanced	194	PS (0 v. 1), LDH (≤IULN v. >IULN), stage (IIIB v. IV), prior weight loss (<5% v. ≥5%), number metastases (0-1 v. >1)	Yes****	3%	374
	S0003 (1)	Advanced	180				
NSCLC Cisplatin+Vinorelbine (n=2)	S9308 (1)	Advanced	189	PS (0 v. 1), LDH (≤IULN v. >IULN), stage (IIIB v. IV), prior weight loss (<5% v. ≥5%), number metastases (0-1 v. >1)	Yes	3%	376
	S9509 (1)	Advanced	187				
Ovarian * Paclitaxel (n=1)	S9701 (2)	FIGO Stage III (A, B, or C) or IV; CR from prior platinum and paclitaxel-based regimen	241	Prior paclitaxel dose (<24 hours v. ≥24 hours), stage (optimal III v. suboptimal III v. IV), age (≤65 years v. >65 years)	Yes	42%	241

Supplemental Table 1. Cancer types, common treatments and SWOG trial arms analyzed (continued)

Cancer Type Common Treatment (# of trials)	Trial (Arm No.)	Disease Description	N	Prognostic Factors Included in Regression	Dose/M^2 BSA?	% Alive at 5 years	Total Sample Size
Prostate *** Docetaxel (n=1)	S9916 (1)	Metastatic, Stage D1 or D2, hormone refractory	348	Progression status (measurable disease v. PSA only), bone pain (grade <2 v. ≥2), PS (0-1 v. 2-3)	Yes	2%	348
Prostate *** Combined ADT (n=1)	S9346 (2)	Stage D2	1251	PS (0-1 v. 2), disease severity (minimal v. extensive), prior hormone therapy (neoadjuvant v. finasteride v. neither)	No	54%	1,251
Renal α-IFN (n=2)	S8949 (2)	Advanced	208	Disease type (evaluable v. measurable), PS (0 v. ≥1), lung metastasis (no v. yes)	Mix*****	7%	263
	S9012 (1)	Advanced	55				
Sarcoma Imatinib (n=1)	S0033 (2)	GIST, Unresectable	608	Disease type (measurable v. non-measurable), PS (0-2 v. 3)	No	48%	608
TOTAL	**14 analyses from 22 studies**				**Yes = 10 No = 3 Mix = 1**		**N=11,724**

Abbreviations: 5FU, 5-fluorouracil; a-IFN, interferon alpha; AC, doxorubicin, cyclophosphamide; ADT, androgen deprivation therapy; AML, acute myelogenous leukemia; ara-C, cytarabine; BCG, bacillus Calmette-Guerin; BMI, body mass index; CAF, cyclophosphamide, doxorubicin, and 5-fluorouracil; CHOP, cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; CR, complete response; DNR, daunorubicin; GIST, gastrointestinal stromal tumor; IULN, institution upper limit of normal; KM, Kaplan Meier estimate; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; P, paclitaxel; PS, performance status; tx, treatment

All trials are phase III except S9500 (AML) and S9012 (renal), which are phase II.

* Women only

** Patients evaluable in the main trial were included in the analyses.

*** Men only

**** Paclitaxel dosed per m^2 of body surface area (BSA). Carboplatin dosed per AUC=6 by modified Calvert Formula (substituting calculated creatinine clearance – as a function of age, weight, sex, and serum creatinine – for glomerular filtration rate (GFR).

***** Dosed per m^2 for S8949 but not for S9012.